New CRISPR technique could alter the way we look at brain diseases
Researchers may have fundamentally altered the way scientists study brain diseases with new CRISPR technology.
List view / Grid view
Researchers may have fundamentally altered the way scientists study brain diseases with new CRISPR technology.
A research team have used genome editing to correct two of the mutations that cause cystic fibrosis.
Scientists report how editing a portion of stem cells with CRISPR-Cas9 is sufficient for long-term reactivation of therapeutic haemoglobin.
Salk scientists discover a pair of enzymes that drive non-small-cell lung cancer by promoting inflammation which could inform the development of new therapies.
Researchers have successfully used a no-cut CRISPR gene editing technique as a therapy for muscular dystrophy in mice models.
Researchers used screening to discover genes that protect the body against the Zika virus, which could inform potential therapies against the virus.
A study has used new synthetic lipids to deliver CRISPR gene editing tools into cells with up to 90 percent efficiency.
A research team have developed a new CRISPR platform called RESCUE (RNA Editing for Specific C to U Exchange).
Researchers have generated images of CRISPR-Cas9 gene editing for the first time, enabling improvement of the technique.
A new study has used combined therapies to eliminate HIV from mice models, providing potential future cures.
Researchers have analysed the physical origin and biological consequences of DNA-RNA hybrids which could inform gene therapies.
The patent office has declared an interference between 10 University of California (UC) patent applications.
Researchers announce positive pre-clinical results for two sickle cell disease treatment strategies.
Researchers have presented their new technology for accurately inserting genes into the genome without cutting DNA.
The advent of CRISPR/Cas9 gene editing, together with the plummeting cost of whole-genome sequencing, has cleared a path for the development of customised cancer cell models. Here, we discuss recent developments in the field and challenges associated with targeted-therapy resistance.